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Amyloid aggregation has been related to an increasing number of human illnesses,
from Alzheimer’s and Parkinson’s diseases (AD/PD) to Creutzfeldt-Jakob disease.
Commonly, only prions have been considered as infectious agents with a high capacity
of propagation. However, recent publications have shown that many amyloid proteins,
including amyloid β-peptide, α-synuclein (α-syn) and tau protein, also propagate in a
“prion-like” manner. Meanwhile, no link between propagation of pathological proteins
and neurotoxicity has been demonstrated. The extremely low infectivity under natural
conditions of most non-prion amyloids is far below the capacity to spread exhibited
by prions. Nonetheless, it is important to elucidate the key factors that cause non-
prion amyloids to become infectious agents. In recent years, important advances in our
understanding of the amyloid processes of amyloid-like proteins and unrelated prions
(i.e., yeast and fungal prions) have yielded essential information that can shed light on the
prion phenomenon in mammals and humans. As shown in this review, recent evidence
suggests that there are key factors that could dramatically modulate the prion capacity
of proteins in the amyloid conformation. The concentration of nuclei, the presence of
oligomers, and the toxicity, resistance and localization of these aggregates could all be
key factors affecting their spread. In short, those factors that favor the high concentration
of extracellular nuclei or oligomers, characterized by small size, with a low toxicity
could dramatically increase prion propensity; whereas low concentrations of highly toxic
intracellular amyloids, with a large size, would effectively prevent infectivity.
Keywords: Alzheimer’s disease, amyloid, amyloid cytotoxicity, amyloid transmission, Creutzfeldt-Jakob disease,
prion, transmissible spongiform encephalopathy
INTRODUCTION
Many neurodegenerative diseases are characterized by the aggregation of misfolded proteins in
the brain, the so-called amyloids. Among these disorders are the prion diseases (Creutzfeld-Jakob
disease in humans, bovine spongiform encephalopathy in cattle or scrapie in sheep) and non-prion
diseases (Alzheimer’s disease (AD), Parkinson’s disease (PD) or tauopathies). The presence
of amyloids in neurodegenerative diseases appears to be a truly generic phenomenon. As a
differential property, prion diseases are assumed to be transmissible whereas non-prion diseases
are non-transmissible.
In prion diseases, through a polymerization process, the misfolded proteins (the prions)
become a self-perpetuating infectious agent. In this way, they can become neurotoxic
Frontiers in Molecular Neuroscience | www.frontiersin.org 1 April 2016 | Volume 9 | Article 29
Espargaró et al. Key Points for Prion-Like Invasion
elements in mammals or protein-based genetic elements in fungi
(Chien et al., 2004; Aguzzi and Calella, 2009). In mammals,
the central event in prion pathogenesis is the conformational
conversion of the normal host prion protein (PrPC) into an
abnormal protease-resistant form (PrPSc) associated with disease.
PrPSc propagates by imposing its abnormal conformation
on other PrPC molecules. But this does not explain how
infectious prions proceed to induce the spongy brain lesions
of transmissible spongiform encephalopathies and, eventually,
extensive neuronal death (Aguzzi, 2005; Chesebro et al.,
2005). Hence, although the presence of PrPSc has generally
been assumed to be constitutional of neurotoxicity, at the
present, PrPSc itself is considered innocuous. In conclusion, the
dissociation of the toxic species (what actually kills neurons) and
infectious agent (the propagating PrP) has been well established
(Hill and Collinge, 2003a,b; Mallucci et al., 2003; Sandberg et al.,
2011). Meanwhile, most prion infectious agents are relatively
species specific, but cross-species transmissions have occurred in
nature and in laboratory experiments (Race et al., 2015).
In non-prion diseases, a host-derived protein is misfolded
and persists in an aggregated form that may damage nearby cells
[β-amyloid (Aβ) in AD, α-synuclein (α-syn) in PD, and tau-
protein (τ) in tauopathies and AD (Costanzo and Zurzolo,
2013; Goedert, 2015)]. Although prions and amyloids
related to non-prion diseases share structural properties
and their conformation, only a small handful of non-prion
amyloids display the main prion behavior, i.e., the capacity
to spread the self-propagating misfolded proteins from
neuron to neuron throughout the brain. In recent years,
evidence for prion-like mechanisms in neurodegenerative
diseases has come to light. Thus, proteins such as τ
(Polymenidou and Cleveland, 2012; Walker et al., 2013;
Goedert et al., 2014; Holmes and Diamond, 2014; Hyman,
2014; Clavaguera et al., 2015; Polanco and Götz, 2015),
α-syn (Hansen et al., 2011; Freundt et al., 2012; Polymenidou
and Cleveland, 2012; Spillantini and Goedert, 2013; Goedert
et al., 2014; Reyes et al., 2014; Herva and Spillantini, 2015), Aβ
(Bahr et al., 1998; Kane et al., 2000; Meyer-Luehmann et al.,
2006; Eisele et al., 2010; Münch et al., 2011; Nath et al., 2012;
Stöhr et al., 2012; Walker et al., 2013), huntingtin (Ren et al.,
2009; Trevino et al., 2012; Banez-Coronel et al., 2015), SOD1
(Münch et al., 2011; Polymenidou and Cleveland, 2011) or
TDP-43 (Furukawa et al., 2011) have been shown to undergo
seeding aggregation in cell cultures, and some of them even
exhibit trans-cellular propagation and the induced spread of
pathology in vivo (Goedert et al., 2010; Kaufman and Diamond,
2013). That the conformational changes undergone by τ, Aβ,
and α-syn could spread between cells was first established in
cell models (Petkova et al., 2005; Desplats et al., 2009; Frost
et al., 2009). Like classical prions, these proteins form distinct
conformers in vivo, and Aβ, mutant τ, and mutant α-syn can
cause the spread of regional pathology and disease progression
in mouse models (Aguzzi and Rajendran, 2009; Clavaguera
et al., 2009; Jucker and Walker, 2011; Luk et al., 2012; Mougenot
et al., 2012; Stöhr et al., 2012). Moreover, the propagation
and misfolding of wild type α-syn have also been reported
(Luk et al., 2012; Masuda-Suzukake et al., 2013); although it
has never been shown to invade neurons. Neuronal invasion
entails dissemination through the peripheral (spleen) and central
nervous system (CNS) via distal neuronal spreading, as well
as individual-to-individual infection under natural conditions.
Thus, the capacity of non-prion amyloids to spread is limited to
neuron-to-neuron transmission (Desplats et al., 2009; Freundt
et al., 2012; Soto, 2012; Reyes et al., 2014). As in prions, the
spread of misfolded protein in non-prion amyloids is not
evidence of neurodegeneration (Halliday et al., 2014). That is,
misfolded proteins in non-prion amyloids can propagate in
a ‘‘prion-like’’ manner, but that spreading is, at least partly,
separate from neurotoxicity.
Recent advances in the field of conformational diseases, and
especially in our understanding of unrelated PrP prions (i.e.,
yeast and fungal prions), have shed some light on the key factors
that determine the capacity of any amyloid to spread. We now
have some indication of which factors limit or favor neuron-to-
neuron transmission and distal neuronal spreading (Figure 1).
In mammals and humans, the prion-like capacity to spread
FIGURE 1 | Amyloid transmission mechanisms. Amyloid aggregates could be transmitted from a sick neuron to healthy neurons via two main mechanisms:
neuron-to-neuron transmission and distal neuronal spreading. The concentration of nuclei, the presence of oligomers, and the toxicity, resistance and localization of
these aggregates are key factors affecting putative neuronal invasion. Note that in order to simplify the figure, only neurons have been considered; nonetheless, it is
important to take into account that astrocytes and other cells can also sporadically generate aggregates.
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within an individual seems to be intimately linked to neuronal
invasion and ultimately to the individual-to-individual infective
capacity.
This review covers the prion-like mechanisms of propagation
involved in the spreading of the amyloid conformation.
Two potential mechanisms for spread within an individual
infected organism (intra-individual spreading) are proposed:
(1) neuron-to-neuron transmission, referring to the infection
of healthy neighboring neurons directly connected to the
infected one; and (2) distal neuronal spreading, entailing
the infection of healthy neurons located far from the
infected one. Moreover, this review attempts to elucidate,
in a simplified form, the key factors that favor or impede
neuron-to-neuron transmission and distal neuronal spreading,
and thus the neuronal invasion capacity and individual-to-
individual infectivity of non-prion amyloids. However, we
are aware that other potential mechanisms, involving cell
types other than neurons, may also be involved in amyloids
spreading. Thus, direct crossing of the blood barrier (Banks
et al., 2009), dissemination via astrocytes and fibroblasts
(Hollister et al., 2015), infection by inducing microglia
recruitment (Baker et al., 2002; Marella and Chabry, 2004;
Pearce et al., 2015; Tu et al., 2015) or spreading via immune
system cells (Isaacs et al., 2006; Bradford and Mabbott, 2012)
represent other potential spreading mechanisms.
NUMBER OF AMASSED NUCLEI
Amyloid fibrillogenesis is a nucleation-dependent process which
depends on protein concentration and can be promoted or
triggered by homologous preformed amyloids that act as
templates in a mechanism known as seeding (Jarrett and
Lansbury, 1993; Chiti and Dobson, 2006). The simplified
nucleation–elongation model is divided into three phases: (1) the
lag phase, when the soluble and monomeric species cluster to
form nuclei; (2) the elongation phase, when monomeric species
are exponentially added to previously formed nuclei, entailing
the formation of transient species such as protofilaments and
protofibrils; and (3) the maturation phase, when the transient
species as well as oligomers are grouped together, leading to
fibril maturation (Jarrett and Lansbury, 1993). However, in a
more realistic scenario, amyloid aggregation has to be considered
as an inter-conversional multi-step equilibrium of numerous
conformational states, which involves a complex network of
equilibriums, wherein secondary nucleation and fragmentation
events are also possible (Chiti and Dobson, 2006; Knowles et al.,
2009; Cohen et al., 2013; Meisl et al., 2014; Sabate, 2014). In vivo,
seeds can trigger amyloid aggregation, promoting the rapid
development of symptoms and increasing the infective capacity
of amyloid-prone proteins (Aguzzi and Calella, 2009; Stöhr et al.,
2012). Thus, the seeding capacity (which is an intrinsic property
shared by all amyloids) of yeast and fungal prions has been
shown in vivo to be intimately related to the number of nuclei
of aggregation per cell as well as the number of amassed nuclei
introduced into the cell, which finally determines the probability
of transmission of the prion (Maddelein et al., 2002; Tanaka
et al., 2006). No relationship has been demonstrated between
seeding capacity and the number of nuclei introduced into
the cell in the case of mammal prions. However, as seeding
is a feature shared by all amyloids, it would seem logical to
extrapolate it to the PrP case. Moreover and very interestingly,
the possibility of a direct relationship between the concentration
of nuclei and the amount of oligomeric material, via ‘‘nucleation
growth’’, has been proposed (Lomakin et al., 1996, 1997; Ferrone,
1999; Serio et al., 2000; Morris et al., 2008; Bemporad and
Chiti, 2012). This suggests that the seeding capacity would be
dependent on the concentration of oligomers (Sakono and Zako,
2010).
In amyloid aggregation, the final concentration of each
amyloid species is highly dependent on both intrinsic and
extrinsic factors. Consequently, modification of the factors
involved in aggregation changes the nucleation and elongation
rates, as well as secondary nucleation or fibril fragmentation.
Moreover, such changes would imply subtle alterations in the
delicate network of equilibriums. It has been shown in fungal
prions that the fragmentation of the chaperone Hsp104 increases
the number of nuclei per cell; such an increment is essential
for prion transmission (Uptain and Lindquist, 2002; Malato
et al., 2007). In short, whereas the amino acid sequence of
any amyloid-prone protein can determine the conformation and
concentration of amyloid species in the network, changes in
the cellular conditions (for instance, as a consequence of stress)
could alter the inter-equilibrium among amyloid states, resulting
in changes in the concentration of nuclei. It should further
be taken into account that specific mutations in the primary
protein sequence could alter the aggregation capacity of amyloid-
prone proteins, entailing changes in the ratios between aggregate
states, which could drastically modify infective capacity (Chiti
and Dobson, 2006; Aguzzi and Calella, 2009). As mentioned
above, seeding capacity is directly related to the number of
seeds (also termed ‘‘events’’ or ‘‘propagons’’ in yeast and fungal
prions) per cell. Furthermore, since seeding is essential for
amyloid transformation, the number of seeds per cell could
become a crucial factor in the amyloid self-assembly process
and in their later propagation. Thus, an increment in the
number of amyloid-like aggregates must favor neuron-to-neuron
transmission.
AGGREGATE SIZE AND SPREADING
CAPACITY
It is widely accepted that both intrinsic structural characteristics
and the size of the species usually formed at the early stages of
amyloid aggregation, i.e., oligomers, protofibrils, protofilaments
and nuclei (amyloid-like species), can be factors that determine
the capacity to spread. Moreover, it has been stated that small
amyloid-like species spread the most (Chiti and Dobson, 2006;
Aguzzi and Calella, 2009; Nath et al., 2012; Figure 1). If we
consider a fixed mass of protein, the size of the aggregates is
inversely proportional to the number of seeds per cell, since
more aggregates of discrete size would have to be formed
to transform soluble protein in its native state into amyloid.
Because small aggregates are the most dispersible amyloid-like
species, an increased number of these favors both neuron-to-
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neuron transmission and distal neuronal spreading. For instance,
PrPSc oligomers, composed of 14–28 monomers, have been
shown to be the most infectious PrP particles (Silveira et al.,
2005).
TOXICITY OF AMYLOID AGGREGATES
The in vivo cytotoxicity derived from amyloid aggregation is a
consequence of an extremely complex and poorly understood
combination of interrelated processes. Among other effects,
it eventually entails the formation of pores, homeostatic
dysfunction and membrane disruption; which seem to be
effects induced by many amyloids (Lashuel et al., 2002; Chiti
and Dobson, 2006; Lashuel and Lansbury, 2006). In addition,
increasing evidence suggests that cell membranes are potential
targets of amyloid aggregates and where much of the molecular
damage they cause occurs (Walker et al., 2006). Interactions of
amyloid aggregates with phospholipid membranes resulting in
lipid peroxidation as well as intracellular aggregation leading to
the impairment of cellular functions are believed to be potential
causes of later cell death (Walker et al., 2006). Crucially, evidence
increasingly indicates that the inherent cytotoxicity of amyloids
depends of the amyloid state (Lashuel et al., 2002; Chiti and
Dobson, 2006; Lashuel and Lansbury, 2006). Thus, oligomers are
usually proposed as one of the most toxic species (Ono et al.,
2009; Bemporad andChiti, 2012). It has been suggested that small
amyloid-like aggregates, ranging from 5 to 30 monomers, and
to a lesser extent mature fibers could principally be responsible
for amyloid toxicity and prion infectivity (Prangkio et al., 2012).
The debate concerning the relationship between infectivity and
neuronal degeneration is far from resolved; but recent evidence
from fungal prions shows that the presence of extremely toxic
oligomeric species fully prevents prion propagation (Greenwald
et al., 2010; Mathur et al., 2012; Seuring et al., 2012). In summary,
for aggregates of the same size, higher toxicity seems to be
associated with lower infectivity; while less toxic aggregates
would be the most infectious (Sabate, 2014). For instance, it
could be speculated that in vivo PrPSc aggregates, which are
highly infectious, possess low toxicity and that they might not
even be toxic particles per se (Silveira et al., 2005; Chiti and
Dobson, 2006; Aguzzi and Calella, 2009). In contrast, in vitro
PrPSc oligomers, sometimes not considered to be bona fide
authentic PrPSc, display extreme toxicity and lack infectivity
(Simoneau et al., 2007). In the same way, Aβ aggregates, widely
accepted as displaying high toxicity, have largely been considered
as non-infectious (Canevari et al., 2004; Chiti and Dobson, 2006;
Aguzzi and Calella, 2009). Although certain infectivity under
forced conditions in primates and transgenic mice (e.g., by intra-
cerebral inoculation) has been observed in recent years (Walker
et al., 2006), infection under natural conditions has never been
demonstrated.
Interestingly, toxicity could exert a dual effect on the infective
capacity of amyloids. Intracellular amyloids, which have to
diffuse from the neuron to the extracellular matrix, require
both passive and active mechanisms (Visanji et al., 2013).
On the one hand, neuron death, entailing a lack of active
mechanisms for amyloid diffusion, could act as a limiting
factor in amyloid distribution. Nevertheless, it is important
to take into account that, in certain cases, toxicity could also
provoke membrane disruption thereby favoring the opposite
effect: the extracellular release of aggregation nuclei. Thus, toxic
aggregates may kill cells and thereby be freely released into
the medium, increasing their chances of spreading. On the
other hand, neuron apoptosis and death entails the inhibition
of cellular protein production and hence a reduction in the
putative amyloid fibrillogenesis, affecting both intracellular and
extracellular amyloids. Consequently, high amyloid toxicity
involves accelerated neuron death and consequently a premature
end to the amyloid process. Since under these conditions self-
polymerization is aborted in the early stages, the final amount
of aggregated protein will tend to be extremely low, thereby
drastically reducing infectivity. These concomitant processes
greatly limit potential amyloid dissemination from the neuron to
the extracellular matrix, and the number of nuclei per neuron.
Thus, while amyloid toxicity is responsible for neurological
damage, high toxicity levels would reduce the capacity of the
amyloid to spread.
AMYLOID RESISTANCE
High resistance to denaturation could be considered another
generic intrinsic characteristic of amyloids and prions. Infectious
PrPSc displays the relevant physical, chemical and enzymatic
resistance (Sabate, 2014), entailing insufficient cellular clearance,
bioavailability, transport and spreading (Aguzzi and Calella,
2009; Soto, 2012; Domert et al., 2014). Since PrPSc cannot
easily be degraded by neuronal proteases, the infectious protein
persists in the cell, potentiating the seeding capacity and
distribution possibilities, and thereby amplifying the infection
process.
Importantly, although not yet proven in mammal and human
prions, fibril resistance to denaturation could be a key factor in
the fragmentation of amyloids. Thus, high resistance has typically
been associated with increased fibril rigidity in yeast prions
(Tanaka et al., 2004; Castro et al., 2011); this in turn is linked to
fragmentation capacity. In this way, more rigid amyloids are not
effectively fragmented and generate seeds less efficiently. Since
all amyloids appear to show enclosed features, the possibility that
a high rate of fibril fragmentation would to be required to favor
the spreading of prions would have to be taken into account for
all amyloids, including PrP. In summary, the presence of brittle
amyloid fibrils increases the number of aggregation nuclei and
thereby promotes prion spreading.
AMYLOID LOCATION
Amyloid location could be a key factor for later spreading.
We can envisage two different scenarios: the spreading of
extracellular (e.g., Aβ and PrPSc) or intracellular (e.g., α-
syn, τ or huntingtin protein) amyloids (Sabate, 2014). In
the extracellular case, the aggregation process occurs on the
extracellular membrane surface, and directly enables both
neuron-to-neuron transmission and distal neuronal spreading.
In contrast, in intracellular amyloids, the aggregation process
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occurs in the cytosol or nucleus of the neurons, meaning
that potential seeds have to be: (1) leaked from an injured
neuron to the extracellular matrix; and then (2) internalized
from the external matrix into healthy neurons via passive or
active mechanisms (i.e., including transference via exocytosis
and endocytosis, accumulation into exosomes or micro-vesicles,
tunneling nanotubes, tubular membrane bridges interconnecting
neurons, and direct synaptic contact; Sherer and Mothes, 2008;
Aguzzi and Calella, 2009; Emmanouilidou et al., 2010; Visanji
et al., 2013; Narkiewicz et al., 2014). Importantly, whereas
neuron-to-neuron transmission could occur via both passive and
active mechanisms, distal neuronal spreading is limited to active
secretory processes via exocytosis–endocytosis. This suggests
that cell death, implying the suppression of active secretion
mechanisms, could be extremely unfavorable for spreading;
in particular for intracellular amyloids. Although increasing
evidence suggests the presence of intracellular amyloids in
extracellular biological fluids such as the cerebrospinal fluid,
human plasma or saliva (El-Agnaf et al., 2003; Arnoys andWang,
2007; Devic et al., 2011; Visanji et al., 2013), the concentration
of these amyloid-like aggregates in extracellular fluids is very
limited. Interestingly, this concentration is expected to be higher
in the inter-neuronal space. This would suggest that, although
drastically limited, neuron-to-neuron transmission would still be
possible, whereas the distal neuronal spreading would be highly
improbable.
CONCLUDING REMARKS
As sketched here, infective capacity could be considered a
generic property shared by all amyloids. However, there are
several factors that modify the possibility of a non-prion amyloid
exhibiting all the properties of a prion. In brief, those factors
that favor a high concentration of extracellular nuclei of low
toxicity, characterized by a limited size, could dramatically
increase prion propensity; whereas, a low concentration
of highly toxic large intracellular amyloids would prevent
infectivity. Consequently, in humans and mammals, although
several amyloid-prone proteins can display certain neuron-
to-neuron transmission, distal neuronal spreading as well as
other potential distribution mechanisms involving not only
neurons (e.g., direct crossing of the blood brain barrier or via
microglia and immune system cells) required for individual-to-
individual infection, have proven to be insufficient to provoke
prion activity under natural conditions. Thus, individual-to-
individual infection currently seems to remain restricted to
PrP.
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